IRADIMED Corporation reported its financial results for the quarter ended June 30, 2026, revealing a slight increase in revenue and a decrease in net income compared to the same period last year. The company generated revenue of $20.5 million, a 0.5% increase from $20.4 million in the second quarter of 2025. However, net income fell to $5.2 million, or $0.41 per diluted share, down from $5.8 million, or $0.45 per diluted share, in the prior year. The decline in profitability was attributed to increased costs associated with new product manufacturing and operational inefficiencies.
In terms of operational performance, IRADIMED's revenue from U.S. sales decreased by 8% to $16.7 million, while international sales surged by 69% to $3.7 million. The company noted that domestic sales accounted for 82% of total revenue in the latest quarter, down from 89% in the same quarter of 2025. The revenue from device sales also saw a decline, dropping to $13.8 million from $14.6 million year-over-year. Conversely, revenue from disposables and extended maintenance agreements increased, contributing to the overall revenue growth.
The company’s balance sheet showed improvements, with total assets rising to $115.0 million as of June 30, 2026, compared to $108.8 million at the end of 2025. Cash and cash equivalents increased to $59.1 million, up from $51.2 million. Stockholders' equity also grew to $101.7 million, reflecting a strong financial position. The company maintained a workforce of 29 field sales representatives and 4 regional sales directors in the U.S., supplemented by 11 clinical application specialists, indicating a stable operational structure.
Looking ahead, IRADIMED anticipates higher revenue for the fiscal year 2026 compared to 2025, driven by increased sales of medical devices and related products. However, the company also expects a rise in operating expenses due to higher sales and marketing costs, as well as regulatory and administrative expenses. The management remains cautious about potential impacts from geopolitical developments and ongoing tariff evaluations, which could affect future operations and financial results. The company has not experienced significant adverse effects from these factors to date but continues to monitor the situation closely.
About IRADIMED CORP
Iradimed Corporation develops MRI-compatible medical devices, including infusion pumps and vital signs monitors, designed for safe operation within strong magnetic fields. Its products serve hospitals and critical care facilities worldwide, enabling safe, accurate patient monitoring and fluid delivery during MRI procedures. The company’s innovative, non-magnetic technology offers a competitive advantage in the expanding MRI safety market, focusing on patient safety, workflow efficiency, and regulatory compliance.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov